SEI Investments’s Nurix Therapeutics NRIX Stock Holding History

SEI Investments’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.82M	Buy	160,934 +53,424	+50%	+$1.33M	﹤0.01%	1601
2026 Q2	$2.61M	Buy	107,510 +25,402	+31%	+$433K	﹤0.01%	1818
2026 Q1	$1.27M	Buy	82,108 +46,132	+128%	+$765K	﹤0.01%	2232
2025 Q4	$682K	Buy	+35,976	New	+$517K	﹤0.01%	2365
2025 Q3	–	Sell	-13,833	Closed	-$158K	–	2881
2025 Q2	$158K	Hold	13,833	–	–	﹤0.01%	2615
2025 Q1	$164K	Buy	+13,833	New	+$231K	﹤0.01%	2504

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.6B AUM 38.62% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

SEI Investments's NRIX Position: Q3 2026 in Review

SEI Investments increased its Nurix Therapeutics (NRIX) stake by 50% in Q3 2026, buying an estimated $1.33M and bringing the position to 160,934 shares worth $3.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1601.

SEI Investments first reported a position in NRIX in Q1 2025 and has held it in 6 quarters since. 91 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

SEI Investments held 160,934 shares of Nurix Therapeutics worth $3.82M as of Q3 2026.
SEI Investments bought 53,424 Nurix Therapeutics shares in Q3 2026, an estimated $1.33M.
Nurix Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q3 2026, its #1601 holding.
SEI Investments first reported a position in Nurix Therapeutics in Q1 2025 and has held it in 6 quarters since.
91 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on SEI Investments's 13F filing for Q3 2026, filed 10 Nov 2026.